The novel class of GLP-1 receptor agonist and GIP dual medications, such as tirzepatide, semaglutide, and the recently introduced retatrutide, offer promising advances in diabetes management . Despite https://retatrutide195265.1blogtheme.com/62094968/retatrutide-one-thorough-look